Salud financiera de hoja de balance de Kiromic BioPharma

Salud financiera controles de criterios 2/6

Kiromic BioPharma tiene unos fondos propios totales de $-4.5M y una deuda total de $9.7M, lo que sitúa su ratio deuda/fondos propios en -215.2%. Sus activos y pasivos totales son $14.2M y $18.7M respectivamente.

Información clave

-153.5%

Ratio deuda-patrimonio

US$14.00m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$3.20m
Patrimonio	-US$9.12m
Total pasivo	US$21.29m
Activos totales	US$12.17m

Actualizaciones recientes sobre salud financiera

Recent updates

Kiromic Biopharma surges 43% as company to begin lung cancer therapy trial in Q1 next year

Oct 06

Análisis de la situación financiera

Pasivos a corto plazo: KRBP tiene fondos propios negativos, que es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: KRBP tiene fondos propios negativos, lo que es una situación más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: KRBP tiene fondos propios negativos, que es una situación más grave que un alto nivel de endeudamiento.

Reducción de la deuda: KRBP's tiene fondos propios negativos, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: KRBP tiene suficiente cash runway para 3 meses según el último flujo de caja libre declarado [flujo de caja libre]], pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: KRBP se prevé que disponga de suficiente liquidez para 2 meses según las estimaciones de flujo de caja libre, pero desde entonces ha obtenido capital adicional.

Descubre empresas con salud financiera

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Salud financiera de hoja de balance de Kiromic BioPharma

Salud financiera controles de criterios 2/6

Información clave

Actualizaciones recientes sobre salud financiera

Nasdaq to Delist the Securities of Kiromic BioPharma

Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14, 2023, Suspended from Trading on Nasdaq Capital Market

Kiromic BioPharma Receives Non-Compliance Notice from Nasdaq

Nasdaq Grants Extension to Kiromic BioPharma to Regain Compliance

Kiromic BioPharma, Inc. announced delayed annual 10-K filing

Kiromic BioPharma Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Recent updates

Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. Reports Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. Announces Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months

Kiromic Biopharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer

Kiromic Biopharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial

Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer

Nasdaq to Delist the Securities of Kiromic BioPharma

Kiromic Biopharma, Inc. Announces Deltacel™? Phase 1 Clinical Trial Enters Patient Recruitment Phase At Beverly Hills Cancer Center

Kiromic BioPharma, Inc.(OTCPK:KRBP) dropped from NASDAQ Composite Index

Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14, 2023, Suspended from Trading on Nasdaq Capital Market

Less than half of directors are independent

Kiromic Biopharma, Inc. Announces Board Appointments

Kiromic BioPharma, Inc. announced that it has received $2.4 million in funding

Kiromic BioPharma, Inc., Annual General Meeting, Jul 25, 2023

Kiromic Biopharma, Inc Appoints Brian Hungerford as Interim Chief Financial Officer

Kiromic BioPharma, Inc. Announces the Resignation of Dan Clark as Chief Financial Officer

Kiromic Biopharma, Inc. Announces Resignation of Karen Reeves as Director

Kiromic BioPharma Receives Non-Compliance Notice from Nasdaq

Frank Tirelli Resigns His Position as Director and Member of the Audit Committee, and the Nominating and Corporate Governance Committee of Kiromic Biopharma, Inc

High number of new and inexperienced directors

Kiromic BioPharma, Inc. announced that it has received $2 million in funding

Kiromic Biopharma Announces FDA Feedback from Type B Pre-Ind Meeting Confirms Deltacel Development Strategy

Kiromic Biopharma surges 43% as company to begin lung cancer therapy trial in Q1 next year

Gainey Mckenna & Egleston Files the First Class Action Lawsuit Against Kiromic Biopharma, Inc

Nasdaq Grants Extension to Kiromic BioPharma to Regain Compliance

The Klein Law Firm Announces Class Action Complaint Against Kiromic Biopharma, Inc

Gainey McKenna & Egleston Files Class Action Lawsuit Against Kiromic BioPharma, Inc

Kiromic BioPharma, Inc. Appoints Leonardo Mirandola as Chief Scientific Officer

Dr. Leonardo Mirandola is the new Chief Scientific Officer of Kiromic biopharma

High number of new and inexperienced directors

Kiromic BioPharma, Inc. Appoints Pietro Bersani to the Role of Chief Executive Officer, Effective May 10, 2022

Kiromic BioPharma, Inc. Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022

Kiromic BioPharma, Inc., Annual General Meeting, Jun 22, 2022

Kiromic BioPharma, Inc. announced delayed annual 10-K filing

Kiromic BioPharma, Inc. Announces Board Appointments

High number of new and inexperienced directors

Kiromic BioPharma Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

High number of new and inexperienced directors

Kiromic BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $40 million.

Kiromic expands in-house cell therapy manufacturing facility, names new COO

Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy

Kiromic Biopharma, Inc. Announces Identification of Novel Targets for Allogeneic Car Gamma Delta T-Cell Therapy in Solid Tumors Utilizing Kiromic’s Proprietary Artificial Intelligence Engine

Kiromic BioPharma, Inc. Announces FDA IND Submission Forty-Five Days before the end of the Second Quarter: First-In-Human, Off-The-Shelf Chimeric PD1 Switch Receptor - Gamma Delta T-cell Therapy

Kiromic Biopharma, Inc. to Resubmit Two Expanded INDs to the FDA for its Allogenic, Off-the-Shelf Gamma-Delta T cell Therapies for Multiple Solid Tumors

New 90-day high: US$11.81

Kiromic Biopharma, Inc. Enters into A Strategic Alliance Agreement with Leon Office (H.K.) Ltd

New 90-day high: US$10.45

Kiromic Announces License Agreement With Longwood University for chPD1

Kiromic BioPharma, Inc. Announces the Filing of Key European Patents for Its Chimeric PD-1 (chPD1) Target

Kiromic BioPharma, Inc. Announces Submission of Two IND Applications for PD1 Gamma-delta CAR - T cell Therapy with the FDA

Kiromic BioPharma files two IND applications for CAR-T therapy in cancer

Kiromic BioPharma reports Q3 results

Kiromic BioPharma, Inc. Announces Management Changes

Kiromic BioPharma, Inc. has completed an IPO in the amount of $15 million.

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera